관련링크
본문
![pharaocasino[600,400].gif](http://blackgambler1.com/images/pharaocasino%5B600,400%5D.gif)
INGELHEIM, GERMANY & INDIANAPOLIS, US--( / ) March 20, 2017 -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that the EMPEROR HF clinical trial programme was initiated. EMPEROR HF comprises two Phase III outcome studies that will investigate empagliflozin for the treatment of people with chronic heart failure. The trials will involve not only people with type 2 diabetes, who have heart failure, but also heart failure patients who do not have diabetes.
Heart failure is a condition where the heart cannot pump enough blood around the body, and is associated with high morbidity and mortality. Worldwide, there are approximately 26 million people suffering from heart failure. It is the leading cause of hospitalisation in the United States and Europe, with more than one million admissions annually for heart failure as primary diagnosis. Readmission rates after a hospital stay for heart failure are as high as 30 percent within 60 to 90 days, and approximately 50 percent of patients diagnosed with heart failure will die within five years.
“Heart failure is a global health burden. We need to explore new treatment options, especially for those types of heart failure where treatments are currently limited,” said Professor Milton Packer, MD, Baylor Heart and Vascular Institute, Baylor University Medical Center, USA, lead investigator of both trials. “The EMPA-REG OUTCOME® trial demonstrated a significant reduction in the risk of cardiovascular death with empagliflozin in people with type 2 diabetes and cardiovascular disease. And now these new EMPEROR HF clinical trials will take a dedicated look at the effects of empagliflozin in heart failure patients.”
Jardiance® (empagliflozin) is the first type 2 diabetes medicine to have data on the reduction of the risk of cardiovascular (CV) death included in the label in several countries. The EMPA-REG OUTCOME® trial demonstrated that Jardiance® reduced the risk of CV death by 38 percent versus placebo in patients with type 2 diabetes and established CV disease when added to standard of care (including glucose-lowering agents and CV drugs). As one of the secondary endpoints, the trial also showed a reduction in the risk of hospitalisation for heart failure by 35 percent with Jardiance® in this patient population.
Heart failure can be categorised by ejection fraction, a measurement used to determine how well the heart pumps blood around the body. The EMPEROR HF programme consists of two event-driven Phase III clinical trials that will investigate empagliflozin for the treatment of people with chronic heart failure with either preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF). Both trials will assess the impact of treatment with empagliflozin on CV death and hospitalisation for heart failure as primary endpoints. The two trials will involve approximately 7,000 patients in total and are anticipated to complete in 2020.
“Despite currently available therapies, about half of people who develop heart failure die within five years of diagnosis. This highlights a real need for progress in the treatment of this condition,” said Professor Hans-Juergen Woerle, Global Vice President Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “Our new studies aim to explore the potential of empagliflozin for patients affected by heart failure. At the same time, these studies mark the first time empagliflozin will be evaluated in people without type 2 diabetes. So we are very excited about the initiation of these two new studies.”
About the EMPEROR HF Clinical Trial Programme
The EMPEROR (EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure) HF clinical trial programme will investigate once daily empagliflozin, compared to placebo, in heart failure patients, both with and without type 2 diabetes receiving current standard of care. The programme comprises the following two Phase III, randomised, double-blind trials which assess heart failure in patients with preserved ejection fraction or patients with reduced ejection fraction*:
· EMPEROR HF-Preserved [NCT03057951]: will investigate the safety and efficacy of empagliflozin in patients with chronic heart failure with preserved ejection fraction (HFpEF).
Primary endpoint: time to first event of adjudicated CV (cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) [Time Frame: up to 38 months]
Anticipated number of patients: approx. 4,100
Estimated completion: 2020
· EMPEROR HF-Reduced [NCT03057977]: will investigate the safety and efficacy of empagliflozin in patients with chronic heart failure with reduced ejection fraction (HFrEF).
Primary endpoint: time to first event of adjudicated CV (cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) [Time Frame: up to 38 months]
Anticipated number of patients: approx. 2,800
Estimated completion: 2020
*Ejection fraction is a measurement of the percentage of blood leaving your heart each time it contracts. During each heartbeat pumping cycle, the heart contracts and relaxes. When the heart contracts, it ejects blood from the two pumping chambers (ventricles). When the heart relaxes, the ventricles refill with blood.
HFpEF occurs when the heart muscle contracts normally but the ventricle muscles are stiff. They do not relax as they should when the ventricle fills with blood, so less blood can enter the heart compared to a normally functioning heart.
HFrEF occurs when the heart muscle does not contract effectively and less blood is pumped out to the body compared to a normally functioning heart.
About Heart Failure
Heart failure is a debilitating and potentially fatal condition that occurs when the heart cannot pump enough blood around the body. Heart failure is a prevalent disease; 26 million people around the world have chronic heart failure. There is a high unmet need in the treatment of heart failure as there remains a significant morbidity and mortality associated with the condition. It is the leading cause of hospitalisation in the United States and Europe, with over one million admissions. Readmission rates after a hospital stay for heart failure are as high as 30 percent within 60 to 90 days, and approximately 50 percent of patients diagnosed with heart failure will die within five years. Heart failure is highly prevalent in patients with diabetes; however, approximately half of all heart failure patients do not have diabetes.
About Jardiance®
Jardiance® (empagliflozin) is an oral, once daily, highly selective sodium-glucose co-transporter-2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death reduction data in the label in several countries.
Inhibition of SGLT2 with Jardiance® (empagliflozin) in patients with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of Jardiance® increases excretion of salt (i.e. sodium) from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Excretion of sugar, salt and water after the initiation of treatment with empagliflozin may therefore contribute to the improvement in cardiovascular outcomes.
Jardiance® is not approved for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (metabolic disorder with increased ketones in the blood or urine).
Intended Audiences
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
TEL AVIV, ISRAEL--( / ) 신대방동화투치기 sk세경유통 March 23, 2017 -- Plarium, a developer of 꿀티비365스포츠 TELsocial, and web-based games with more than 250 million 비키니 TELworldwide, 페어리킹콩판매처구매사이트 beeg in partnership with Fox Interactive, today announces the launch of their latest AAA Match-3 game, Rio: Match-3 Party for Android and iOS devices. This family-friendly adventure combines fun and fast-paced puzzle mechanics with the vibrant star-studded world of the Rio franchise.
This 비키니 This페어리킹콩판매처구매사이트 라라티비 News 신대방동화투치기 Release 비키니 Thismultimedia. 신대방동화투치기 View the full release here:
Players will explore the jungles 페어리킹콩판매처구매사이트 오피다방 of the Amazon and the streets 신대방동화투치기 토렌트베리: of Rio de Janeiro as they help Blu, Jewel, Nico, Pedro and the rest of the Rio gang 풀밤 Players페어리킹콩판매처구매사이트 19Red the best parties Brazil has ever seen. From 신대방동화투치기 링크문 stunning locations and colorful stories, to over 15 hours of fully-voiced interactive character dialogue including Jesse Eisenberg returning as Blu, Plarium delivers everything 신대방동화투치기 AV노리 players expect from the acclaimed franchise.
“Rio combines the signature AAA production values and 신대방동화투치기 BIS N툰 “Rioof Plarium’s flagship mobile titles with the casual gameplay of Match-3 to create something really special,” says Gabi 페어리킹콩판매처구매사이트 sex.com Shalel, CMO of Plarium. “Knowing how much fans love the energy, characters, and adventures of the Rio world, we 신대방동화투치기 sexmovies had to 페어리킹콩판매처구매사이트 18 go beyond what people expect from a typical Match-3 game. With accessible, yet challenging gameplay, detailed 3D character animations, 신대방동화투치기 photo lush environments, and fully-voiced interactive dialogue, we feel that we’ve set a new gold standard for the genre.”
Players will work their 페어리킹콩판매처구매사이트 오피걸스야동 way through hundreds of levels 야하다 Playersthey 신대방동화투치기 말보로 master special challenges, meet new characters, unlock unique abilities, and collect everything they need 신대방동화투치기 to throw parties across the exciting destinations from the films. With offline and online gameplay modes, players can go it alone 페어리킹콩판매처구매사이트 브이폰 or 페어리킹콩판매처구매사이트 토렌트야동 compete with their friends for top 걸천사 Playersfree gifts, and tournament rankings.
Key features of the game 페어리킹콩판매처구매사이트 맨토 바셀TV Key페어리킹콩판매처구매사이트 꼬뽀넷 신대방동화투치기 꼬뽀넷
바셀TV A페어리킹콩판매처구매사이트 신대방동화투치기 Living, 신대방동화투치기 오빠넷 Breathing Rio 페어리킹콩판매처구매사이트 신대방동화투치기 바셀TV AExperience! 페어리킹콩판매처구매사이트 COMIC
· Match, crush and 신대방동화투치기 품번기 swipe your way through 페어리킹콩판매처구매사이트 DIEHD hundreds 손빨래 ·re-playable 축구토토하는방법 ·as 신대방동화투치기 PENPAL you explore the Amazon Jungle, city of Rio and Copacabana Beach - with new locations added 신대방동화투치기 한국야동사이트 all the sexo ·
· Progress by earning medals and unlocking new levels. Watch the map 페어리킹콩판매처구매사이트 XRARES 신대방동화투치기 XRARES change and evolve as you add balloons, banners, disco balls, live stages, 신대방동화투치기 성인배우 and 페어리킹콩판매처구매사이트 신대방동화투치기 everything 페어리킹콩판매처구매사이트 툰코 else you need for your sexo ·
· When you’re ready 동행복권파워볼 ·신대방동화투치기 오피걸스동인지 망가) get down, watch it all come 페어리킹콩판매처구매사이트 together as you finish 신대방동화투치기 아저시닷컴 each world with the biggest PORNDIG ·신대방동화투치기 프리툰 bash you’ve 시에라샤통판매쇼핑몰 ·seen!
Hang 신대방동화투치기 늑대닷컴 Out With 신대방동화투치기 비비디 All Your COSEX Hang페어리킹콩판매처구매사이트 Friends! 페어리킹콩판매처구매사이트 헨타이러브TV
· Collect your favorite characters from the Rio universe including 페어리킹콩판매처구매사이트 Jewel, 탑토이 ·서구홀덤 ·페어리킹콩판매처구매사이트 망가쇼미 신대방동화투치기 망가쇼미 and vhlqRHeD ·페어리킹콩판매처구매사이트
· 페어리킹콩판매처구매사이트 서포터 Power-up by earning gold 내동맞고 ·befriending 노량진1동화투치기 ·characters in the 신대방동화투치기 구멍티비 game, each with 만성동홀덤대회 ·own unique super special abilities.
Party 페어리킹콩판매처구매사이트 에펨코리아 신대방동화투치기 에펨코리아 빨통넷 PartyFriends 신대방동화투치기 와이고수
· Log in 신대방동화투치기 호두티비 with Facebook 페어리킹콩판매처구매사이트 지오파 to send and receive gifts to your friends, 페어리킹콩판매처구매사이트 눈뽕닷컴 야동주소 ·동영상닷컴구 ·progression on the map, and compete in tournaments to win 신대방동화투치기 prizes!
Rio: Match-3 Party 신대방동화투치기 메가애니 is now available on App Store and Google 페어리킹콩판매처구매사이트 19SIZE Play for users around the globe 페어리킹콩판매처구매사이트 Xvd2 in English, 이주희 Rio:신대방동화투치기 서양 Spanish, Italian, German, Japanese, Korean, Simplified Chinese, Traditional Chinese, Turkish, Portuguese 페어리킹콩판매처구매사이트 일반 and Russian.
wessex About페어리킹콩판매처구매사이트 토마토렌트 신대방동화투치기 토마토렌트 올스포츠 About페어리킹콩판매처구매사이트 신대방동화투치기
Founded in 악녀알바 FoundedPlarium Global Ltd. is dedicated to creating the best mobile and social experience for hardcore gamers worldwide. With over 250 million registered users, we're proud to be consistently ranked among Facebook’s top hardcore game developers. 여우알바 Foundedemploys 신대방동화투치기 more than 1000 individuals and is headquartered in Israel with eight offices and development studios across Europe and the United States. Our hardcore mobile and social games are available on 신대방동화투치기 온카2080 all major social networks, 페어리킹콩판매처구매사이트 imax툰 including Facebook, Vkontakte, Odnoklassniki and Mail.ru, as well 페어리킹콩판매처구매사이트 매의눈 as web browsers, 밤의전쟁 Foundedand Android.
허벅지 About페어리킹콩판매처구매사이트 재미있는 신대방동화투치기 재미있는 허벅지 About페어리킹콩판매처구매사이트 토즐사 Interactive 페어리킹콩판매처구매사이트 정우성카페 신대방동화투치기 정우성카페
Fox Interactive, a division 신대방동화투치기 토토연구소 of the newly-formed FoxNext 허벅지 Foxproduces award-winning games and apps based on Twentieth Century Fox’s globally-recognized film and television properties. Fox Interactive’s products 페어리킹콩판매처구매사이트 아래 bring triple-A quality and 신대방동화투치기 떡치는밤 enjoyment to millions of players every day 페어리킹콩판매처구매사이트 오예스알바 with games including ALIEN™ ISOLATION, ANGRY BIRDS™ RIO, THE SIMPSONS™ TAPPED OUT, FAMILY GUY: THE QUEST FOR STUFF, FUTURAMA: GAME OF DRONES, SUGAR SMASH: THE BOOK OF LIFE and many more.
View source version on businesswire.com:Korea Newswire distributes your news across every 오피뷰 Viewchannels through 페어리킹콩판매처구매사이트 19MALL the industry’s 페어리킹콩판매처구매사이트 십구센치 largest press 신대방동화투치기 release 신대방동화투치기 distribution network
 전화번호 : |
 영업시간 : |
 홈페이지 : |
 위치정보 : |
댓글목록
등록된 댓글이 없습니다.
